Dr. Samuel A. Shelburne, MD

Dr. Shelburne practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Shelburne's NPI, 1841389319, was assigned on October 12, 2006. Dr. Shelburne graduated from UTMB Health in 1998. Dr. Shelburne holds Texas license L2641.

Dr. Shelburne's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Shelburne's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shelburne practices. Vendor and product names are available with a free account.

Infectious disease is Dr. Shelburne's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Shelburne is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Shelburne's licenses on file in 10 states: Texas, Florida, Georgia, Arizona, Louisiana, Mississippi, Tennessee, Washington, Alabama and Oklahoma.

Dmand AI lists acute skin infection, pneumonia, UTI and yeast infection among the conditions Dr. Shelburne treats.

CMS data shows 216 Medicare services from Dr. Shelburne across 7 procedure codes in 2024, for 113 Medicare patients. Medicare paid $19,568 for them.

CMS counts 113 Medicare patients who saw Dr. Shelburne in 2024. The largest group is 65 to 74, with 53 patients. 75% of them have high blood pressure, and 64% have high cholesterol. Their average risk score is 3.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shelburne's median patient age at 70, with 52% women.

In 2024, Dr. Shelburne wrote 82 Medicare Part D claims for 24 patients. 93% of them were for generic drugs. CMS names the drug for 50 of them, across 4 drugs with 11 or more claims each, at $556 in total drug cost. In 2023, CMS named 65 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Shelburne for performance year 2024, reported as part of a group. Dr. Shelburne accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shelburne as offering telehealth.

Dmand AI links 95 papers to Dr. Shelburne, published from 2005 to 2025. 2017 was the busiest year, with 9. The most frequent topics are Anti-Bacterial Agents, Streptococcus pyogenes and Bacterial Proteins. Dr. Shelburne has published most often in Clin Infect Dis. Dr. Shelburne's most frequent co-authors are Cesar A. Arias, MD, Kenneth V. Rolston, MD and William Robert Miller, MD.

Dr. Shelburne graduated from UTMB Health in 1998.

Dr. Shelburne is in network with 4 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 3. Check the plan with the practice before a visit.